

REMARKS

Applicant respectfully requests entrance of the amendments as detailed above in the above-referenced patent application.

Applicant respectfully submits that the deletion of any claims and any other loss of claimed subject matter is being made solely to expedite prosecution of one aspect of the invention and is not meant to impact Applicant's right to pursue the canceled claims or subject matter. Applicant is submitting their amendments without prejudice to the subsequent prosecution of claims to some or all of the subject matter which might be lost by virtue of this paper. Applicant explicitly reserves the right to pursue the subject matter of any of the canceled claims, or some or all of the subject matter which might be lost by virtue of this paper, in Divisional or Continuation Applications.

No new matter is being introduced by the present amendments. Rather, amendments are being made to more particularly claim what Applicants regard as their invention. Specifically, claims 56 and 76, as amended, recite a multi-antigenic glycopeptide comprising a peptidic backbone made up of 2 to 25 amino acid residues, wherein two or more of said amino acids is independently substituted with a glycosidic moiety. The multi-antigenic glycopeptide peptidic backbone is defined as having 2-25 amino acyl residues. Support for the upper limit of 25 amino acyl residues can be found, for example, in original claim 28, which defines the peptidic backbone of the glycopeptide as an oligopeptide comprising up to 5 amino acyl residues ($m=1-3$) attached to a linker which may be an oligopeptide comprising 2-20 amino acyl residues. Original claim 28 therefore allows for a glycopeptide comprising a maximum peptidic backbone of 25 amino acyl residues. This feature has been introduced into claims 56 and 76. The language "wherein two or more of said amino acids is independently substituted with a glycosidic moiety" finds support throughout the specification, figures and claims, as originally filed, in the teaching of multi-antigenic glycopeptides (*i.e.*, comprising two or more carbohydrate antigens). In addition, claims 56 and 76, as amended, recite a glycosidic moiety having the structure: $A-O-(CH_2)_n-$. Support for such language can be found throughout the specification and claims, as originally filed (See for example original claim 28).

The dependency of claims 58, 61, 62, 67, 69-73, 78, 81, 86, 88, 91-93, 95 and 97 has been corrected in view of the cancellation of claims 57 and 77.


Claims 62, 74, 81 and 93, as amended, recite that m may be 1, 2 or 3. Support for this language can be found throughout the specification and claims, as originally filed (See for example original claim 28). In addition, claims 62 and 81 have been amended to re-write the original

definition of the linker into chemical structures in an effort to particularly and distinctly point out what Applicants regard as their invention. Accordingly, "a free carboxylic acid, (carboxamido)alkyl carboxamide, primary carboxamide, mono- or dialkyl carboxamide, mono- or diarylcarboxamide, linear or branched chain (carboxy)alkyl carboxamide, linear or branched chain (alkoxycarbonyl)alkyl-carboxamide, linear or branched chain (carboxy)arylalkylcarboxamide" now reads "-O-, -NR_G-, -NR_G(CR_HR_I)_kNR_J-, -NR_G(CR_HR_I)_kNR_J(C=O)(CR_HR_I)_kS-, -(CR_HR_J)_kNR_I-, -O(CR_HR_I)_kNR_J." Support for recitation of -NR_G(CR_HR_I)_kNR_J(C=O)(CR_HR_I)_kS- can be found, for example, in US patent application No.: 09/083,776 (now patent No.: 6,660,714), the entire contents of which are incorporated in the present application by reference (See lines 18-20 on page 33 of the specification, as filed).

Applicant thanks the Examiner for her time and consideration. If a telephone conversation would help clarify any issues, or help expedite prosecution of this case, Applicant invites the Examiner to contact the undersigned at (617) 248-5150.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required for consideration of this paper are authorized to be charged to our Deposit Account No. 03-1721.

Respectfully submitted,
CHOATE, HALL & STEWART LLP



Nadège M. Lagneau, Ph.D.
Reg. No. 51,908

Dated: July 18, 2005

PATENT GROUP
CHOATE, HALL & STEWART, LLP
Two International Place
Boston, MA 02110
Telephone: 617-248-5150
Facsimile: 617-248-4000